Nanobiotix S.A.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NANO.PA | INBX | NRIX | VIR | BHVN | 688382.SS | |
|---|---|---|---|---|---|---|
| Market cap | 1.40B | 1.28B | 1.74B | 1.99B | 2.30B | 8.38B |
| P/E (TTM) | — | — | 6.6 | — | — | — |
| Forward P/E | -109.8 | -9.9 | -12.5 | -4.8 | -8.2 | -43.8 |
| Price/book | -41.8 | -24.1 | 1.8 | 2.1 | -23.4 | 6.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +53.25% | +7.12% | +27.40% | +129.88% | +78.66% | −48.70% |
| Today | +2.09% | +7.01% | −38.23% | +4.90% | −2.37% | +4.33% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All NANO.PA news ›Nanobiotix: The Phase 3 May Come Later, And Lenders Get Paid First
(NASDAQ:NBTX) Seeking Alpha - Nanobiotix S.A. is now primarily dependent on J&J's development and commercialization of its lead asset, JNJ-1900. - NBTX's valuation is heavily tied to Phase 3 trial outcomes, with J&J's timeline sugges
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
Data presented at the 2026 Congress of the European Society for Medical Oncology ABSTRACT #3956: Safety and Anti-Tumor Activity of NBTXR3/SBRT with Immune Checkpoint Inhibitors in Anti-PD-1 Resistant Melanoma: Results from a Phase I Dose…
NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
Data presented at the IASLC 2026 World Conference on Lung Cancer POSTER P2.260: Re-irradiation (ReRT) with NBTXR3 for Inoperable Locoregionally Recurrent Non-Small Cell Lung Cancer (NSCLC): A Phase I Trial Patients who are candidates for…
Nanobiotix reports 51M shares outstanding at Sept. 30
Netflix Reports Q3 2026 Earnings: Revenue Rises 12% to $12.87 Billion, Operating Margin 34.6% Peraso Receives Production Order Exceeding $2.0 Million for 60 GHz Fixed Wireless Access Deployment INOVIO Announces Favorable Judgment in…
Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Stock Has Average Target Price of $46.67 According to Analysts
Posted by Defense World Staff on Oct 19th, 2026 NBTX has been the topic of a number of recent research reports. Guggenheim started coverage on Nanobiotix in a research note on Tuesday, September 15th. They issued a “buy” rating and a…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- defenseworld.net1
- seekingalpha.com1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.